These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 33787580)
21. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447 [TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical p16 overexpression and Rb loss correlate with high-risk human papillomavirus infection in endocervical adenocarcinomas. Yasutake N; Yamamoto H; Kuga R; Jiromaru R; Hongo T; Katayama Y; Sonoda K; Yahata H; Kato K; Oda Y Histopathology; 2024 Jun; 84(7):1178-1191. PubMed ID: 38445509 [TBL] [Abstract][Full Text] [Related]
23. HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports. Arfi A; Hequet D; Bataillon G; Tran-Perennou C; Farkhondeh F; Sastre-Garau X; Fourchotte V; Rouzier R; Laas E; Pouget N; Vincent-Salomon A; Jeannot E BMC Cancer; 2019 Apr; 19(1):375. PubMed ID: 31014281 [TBL] [Abstract][Full Text] [Related]
24. Endocervical adenocarcinoma in situ-from Papanicolaou test to hysterectomy: a series of 74 cases. Lashmanova N; Braun A; Cheng L; Gattuso P; Yan L J Am Soc Cytopathol; 2022; 11(1):13-20. PubMed ID: 34509373 [TBL] [Abstract][Full Text] [Related]
25. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus. Park KJ; Kiyokawa T; Soslow RA; Lamb CA; Oliva E; Zivanovic O; Juretzka MM; Pirog EC Am J Surg Pathol; 2011 May; 35(5):633-46. PubMed ID: 21490443 [TBL] [Abstract][Full Text] [Related]
26. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas. Esheba GE J Egypt Natl Canc Inst; 2013 Jun; 25(2):87-93. PubMed ID: 23719407 [TBL] [Abstract][Full Text] [Related]
27. Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients. Hopley R; Gillespie A Lab Med; 2016 Feb; 47(1):52-6. PubMed ID: 26732782 [TBL] [Abstract][Full Text] [Related]
28. The spectrum of cervical glandular neoplasia and issues in differential diagnosis. Loureiro J; Oliva E Arch Pathol Lab Med; 2014 Apr; 138(4):453-83. PubMed ID: 24678677 [TBL] [Abstract][Full Text] [Related]
29. Ovarian Metastasis from Human Papillomavirus-associated Usual-type Endocervical Adenocarcinoma: Clinicopathological Characteristics for Distinguishing from Primary Ovarian Mucinous or Endometrioid Tumor. Cho YA; Park CK; Kim HS In Vivo; 2024; 38(4):1973-1983. PubMed ID: 38936897 [TBL] [Abstract][Full Text] [Related]
30. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729 [TBL] [Abstract][Full Text] [Related]
31. Minimal-deviation Endometrioid Adenocarcinoma of the Cervix: A Case Report With Ultrastructural Analysis Demonstrating Abnormal Ciliation of the Tumor Cells. Gould PR; Stewart CJR; Papadimitriou JM Int J Gynecol Pathol; 2017 Jan; 36(1):90-94. PubMed ID: 27362904 [TBL] [Abstract][Full Text] [Related]
33. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Rabban JT; McAlhany S; Lerwill MF; Grenert JP; Zaloudek CJ Am J Surg Pathol; 2010 Feb; 34(2):137-46. PubMed ID: 20061933 [TBL] [Abstract][Full Text] [Related]
34. The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions. Danialan R; Assaad M; Burghardt J; Newcomb P; Cartun RW; Mandavilli S Gynecol Oncol; 2013 Aug; 130(2):383-8. PubMed ID: 23618832 [TBL] [Abstract][Full Text] [Related]
35. Cytomorphologic Features of Gastric-Type Endocervical Adenocarcinoma in Liquid-Based Preparations. Schwock J; Starova B; Khan ZF; Mirkovic J; Parra-Herran C; Ko HM; Rouzbahman M; Ghorab Z Acta Cytol; 2021; 65(1):56-66. PubMed ID: 33152741 [TBL] [Abstract][Full Text] [Related]
36. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Staebler A; Sherman ME; Zaino RJ; Ronnett BM Am J Surg Pathol; 2002 Aug; 26(8):998-1006. PubMed ID: 12170086 [TBL] [Abstract][Full Text] [Related]
37. Recent advances in invasive adenocarcinoma of the cervix. Stolnicu S; Hoang L; Soslow RA Virchows Arch; 2019 Nov; 475(5):537-549. PubMed ID: 31209635 [TBL] [Abstract][Full Text] [Related]
38. Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type. Asaka S; Nakajima T; Kugo K; Kashiwagi R; Yazaki N; Miyamoto T; Uehara T; Ota H Virchows Arch; 2020 Apr; 476(4):499-510. PubMed ID: 31932920 [TBL] [Abstract][Full Text] [Related]
39. Synchronous endometrioid adenocarcinomas in the uterine cervix and corpus. Obata T; Nakamura M; Mizumoto Y; Matsumoto T; Takakura M; Fujiwara H J Obstet Gynaecol Res; 2016 Oct; 42(10):1390-1394. PubMed ID: 27354119 [TBL] [Abstract][Full Text] [Related]
40. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Young RH; Clement PB Histopathology; 2002 Sep; 41(3):185-207. PubMed ID: 12207781 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]